Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD, Leading experts in relapsed/refractory multiple myeloma, explore evolving treatment landscapes, including CAR T-cell therapies, the role of selinexor, and optimized sequencing strategies, while addressing two complex clinical scenarios and providing key insights for community oncologists to enhance patient care.
EP. 4: Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM
August 21st 2024The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.
EP. 8: Clinical Insights on the Patient Presentation & Treatment Course
September 4th 2024The panel shares their expert impressions of the case and deliberates on potential treatment strategies for the 53-year-old patient with heavily pre-treated multiple myeloma, considering his prior therapies and current clinical status.
EP. 10: Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM
September 11th 2024The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.